Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Pediatrics ; 97(6 Pt 2): 992-5, 1996 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-8637789

RESUMO

OBJECTIVE: This prospective study was aimed at answering two important questions: 1) Is a biweekly schedule of 1.2 million U intramuscular benzathine penicillin G (BPG) superior to a 4-week one in the prevention of upper respiratory Group A beta-hemolytic streptococcal (GABHS) infections and rheumatic fever (RF) recurrences? 2) Is there a difference in the bioavailability of BPG obtained from different manufacturers? METHODOLOGY: Three hundred sixty rheumatic patients aged 4 to 20 years were randomly assigned to either a biweekly (190 patients) or 4-week (160 patients) BPG prophylactic schedule and were followed-up monthly for 2 years by clinical examination, throat swab culture for GABHS and measurement of antistreptolysin O titer to detect GABHS infection and/or recurrences of RF (according to revised Jones' Criteria). Thereafter, 34 rheumatic subjects, aged 8 to 16 years were randomly assigned to receive a 4-week injection of 1.2 million U of either a locally manufactured BPG brand (22 patients) or an imported one (12 patients). Sera of all patients were tested for penicillin level by plate diffusion method on days 1, 2, 3, 4, 5, 6, 7, 14, 21, and 28 after the intramuscular injection of BPG. RESULTS: The GABHS infection rate was found to be 0.2% and 0.3% for patients on the biweekly and 4-week BPG schedules, respectively, with no significant differences between them. However, the RF recurrence rate/patient/year for the 4-week schedule patients (0.12) was double that for the biweekly schedule ones (0.06). Estimation of the bioavailability of the two different brands of BPG demonstrated a difference in their pharmacokinetics and a decrease in the serum penicillin concentration below the minimum inhibitory concentration 3 weeks after the injection of either brand. CONCLUSION: Although a biweekly schedule may not be superior in preventing upper respiratory GABHS infection, it may play a role in preventing the sequelae of such infections. The short duration of penicillinemia explains the superiority of the 2-week schedule in RF prophylais. The difference in the pharmacokinetics of penicillin brands might contribute to the high recurrence rate of RF reported in Egypt.


Assuntos
Antibacterianos/administração & dosagem , Antibacterianos/uso terapêutico , Penicilina G Benzatina/administração & dosagem , Penicilina G Benzatina/uso terapêutico , Febre Reumática/tratamento farmacológico , Adolescente , Adulto , Criança , Pré-Escolar , Seguimentos , Humanos , Febre Reumática/etiologia , Streptococcus pyogenes/patogenicidade
2.
Int J Clin Pharmacol Ther Toxicol ; 24(8): 433-7, 1986 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-3531035

RESUMO

Thirteen salmonella strains of clinical isolates were tested for serum sensitivity, antibiotic resistance, colicin production and plasmid existence. Nine serum resistant strains were smooth and harboring plasmids of different sizes. Transfer of R-plasmids by conjugation from three strains to E. coli K12 conferred slight decrease in serum sensitivity. Curing the nine resistant strains with ethidium bromide or acriflavine affected their serum resistance, plasmid content and cell surface. Rough isolate of S. johanesberg became serum sensitive after curing the R-factors. The suggested mechanisms involved in the change in serum sensitivity after curing are discussed.


Assuntos
Atividade Bactericida do Sangue , Fatores R/efeitos dos fármacos , Salmonella/efeitos dos fármacos , Acriflavina/farmacologia , Antibacterianos/farmacologia , Colicinas/biossíntese , Conjugação Genética , Resistência Microbiana a Medicamentos , Escherichia coli , Etídio/farmacologia , Humanos , Testes de Sensibilidade Microbiana , Salmonella/genética , Salmonella/metabolismo , Fatores de Tempo
3.
Pharmazie ; 40(9): 650-1, 1985 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-3877939

RESUMO

Combination of amoxycillin (1) and dicloxacillin (2) showed synergistic bacteriostatic and bactericidal activities against 15 clinical isolates of Staphylococcus aureus, including 3 beta-lactamase-producing strains.


Assuntos
Amoxicilina/farmacologia , Dicloxacilina/farmacologia , Staphylococcus aureus/efeitos dos fármacos , Sinergismo Farmacológico , Staphylococcus aureus/enzimologia , beta-Lactamases/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...